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The Ran-binding protein 2 (RanBP2) is a large multimodular and pleiotropic protein. Several molecular partners with
distinct functions interacting specifically with selective modules of RanBP2 have been identified. Yet, the significance
of these interactions with RanBP2 and the genetic and physiological role(s) of RanBP2 in a whole-animal model remain
elusive. Here, we report the identification of two novel partners of RanBP2 and a novel physiological role of RanBP2 in
a mouse model. RanBP2 associates in vitro and in vivo and colocalizes with the mitochondrial metallochaperone,
Cox11, and the pacemaker of glycolysis, hexokinase type I (HKI) via its leucine-rich domain. The leucine-rich domain of
RanBP2 also exhibits strong chaperone activity toward intermediate and mature folding species of Cox11 supporting a
chaperone role of RanBP2 in the cytosol during Cox11 biogenesis. Cox11 partially colocalizes with HKI, thus supporting
additional and distinct roles in cell function. Cox11 is a strong inhibitor of HKI, and RanBP2 suppresses the inhibitory
activity of Cox11 over HKI. To probe the physiological role of RanBP2 and its role in HKI function, a mouse model
harboring a genetically disrupted RanBP2 locus was generated. RanBP2
   /    are embryonically lethal, and
haploinsufficiency of RanBP2 in an inbred strain causes a pronounced decrease of HKI and ATP levels selectively in
the central nervous system. Inbred RanBP2
þ þ/   mice also exhibit deficits in growth rates and glucose catabolism without
impairment of glucose uptake and gluconeogenesis. These phenotypes are accompanied by a decrease in the
electrophysiological responses of photosensory and postreceptoral neurons. Hence, RanBP2 and its partners emerge as
critical modulators of neuronal HKI, glucose catabolism, energy homeostasis, and targets for metabolic, aging
disorders and allied neuropathies.
Citation: Aslanukov A, Bhowmick R, Guruju M, Oswald J, Raz D, et al. (2006) RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes
deficits in glucose metabolism. PLoS Genet 2(10): e177. DOI: 10.1371/journal.pgen.0020177
Introduction
The RanBP2/Nup358 is a unique vertebrate and large
scaffold protein comprised of multiple structural and func-
tional domains [1–4]. Several roles of RanBP2 have emerged
that implicate RanBP2 in nucleocytoplasmic trafﬁcking [3,5],
protein biogenesis [6,7], the formation of the mitotic spindle,
assembly of the nuclear envelope [8], and the integration of
the nuclear envelope breakdown with kinetochore formation
and maturation during early mitotic progression [9]. The
speciﬁc interaction of RanBP2 with a diverse set of partners
likely reﬂects a pleiotropic role of RanBP2 in cell function,
possibly through the integration of multiple pathways. On
the other hand, the cell (tissue)-selective interaction of
RanBP2 with some of its partners may also impart cell-
restricted roles to RanBP2. For example, the Ran-binding
domains RBDn=1-4 of RanBP2 associate with the nuclear
import co-receptor, importin-b [10,11], and antibodies
against RanBP2 inhibit the nuclear import pathway in HeLa
cells [3]; but such a role seems dispensable in Xenopus oocytes
[12]. In addition, the combination of the C-terminal domains,
RBD4 and CY (of RanBP2), associates with a subset of G
protein-coupled receptors, the red/green opsin, expressed in
photosensory neurons and enhances opsin functional
production [6,7], while the interaction of the KBD of RanBP2
with a subset of the conventional microtubule-based motor
proteins, the kinesins, KIF5B and KIF5C, occurs selectively in
the central nervous system (CNS) [13].
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associating speciﬁcally with a selective domain of RanBP2,
are likely to impart and integrate additional roles to RanBP2.
For example, the cyclophilin-like domain (CLD), the internal
repeat (W1W2/IR), and zinc-ﬁnger rich (ZnF) domains of
RanBP2 associate speciﬁcally with components of the 19S cap
of the proteasome [14], the E2 SUMO-1-conjugating enzyme
(Ubc9) [15], and the nuclear export receptor, CRM1/exportin-
1 [16], respectively. RanBP2 itself was also found to exhibit
SUMO1 E3 ligase activity [17], supporting a direct link
between RanBP2-mediated SUMO-1 substrate modiﬁcation
and relocation of SUMO-1 modiﬁed cytosolic substrates (e.g.,
RanGAP) to the cytosolic face of the nuclear pore complex
(NPC) [18]. Finally, RanBP2 was also found to localize
prominently to the mitochondria-rich ellipsoid subcellular
compartment of photosensory neurons [19] and to RanGT-
Pase-restricted foci along cytoplasmic tracks [19], in addition
to its localization at cytoplasmic ﬁbrils emanating from
nuclear pores [2,3,10,12,19].
Emerging evidence supports that the CNS-selective effects
of RanBP2 may also underlie the pathogenesis of certain
neuropathies. Parkin is ubiquitously expressed and interacts
with the Ubc9-interacting domain of RanBP2 [20]. This
promotes the ubiquitination and degradation of RanBP2 [20],
possibly via the interaction of the CLD domain of RanBP2
with the 19S cap subunits of the proteasome [14]. Interest-
ingly, the small yeast Ran-binding protein 1 (RanBP1), Yrb1p,
with strong homology to the Ran-binding domains of
RanBP2, is also required for cell-cycle regulated protein
degradation [21]. Parkin, like RanBP2 [17], has E3-ligase
activity [22–24]; and loss-of-function of parkin leads to early
onset autosomal recessive juvenile Parkinsonism [25]. While
the dopaminergic neuronal-restricted effects of mutations in
parkin are not understood [25], parkin
 /  mice exhibit
mitochondrial dysfunction and energy and growth deﬁcits,
and a fraction of parkin localizes to the cytoplasmic face of
the mitochondria, where together with other partners is
thought to promote the degradation of selective mitochon-
drial substrates and to exert a neuroprotective function [26–
29]. These data suggest that deﬁcits in RanBP2 and parkin
may share (patho) physiological pathways and support a
multifaceted role of RanBP2. Yet clear functions of RanBP2
in animal and cell physiology remain elusive.
Here, we report on the identiﬁcation and function of two
novel partners of RanBP2, Cox11 and hexokinase type I
(HKI), which interact with a large and orphan domain of
RanBP2, the leucine-rich domain (LD); and on the outcome
of partial loss-of-function of RanBP2 on HKI, animal
physiology, and glucose/energy metabolism.
Results
The LD of RanBP2 Interacts with Cox11 and HKI
The LD of RanBP2 (Figure 1A) is a large and orphan
domain of ;700 residues (;80 kDa), for which no molecular
partners have been identiﬁed until this date. Brain and retina
yeast two-hybrid libraries were screened with LD. Cox11 was
identiﬁed as a partner to this domain (Figure 1B and 1C).
Cox11 is a metallochaperone implicated in cytochrome c
oxidase assembly [30,31]. Structure-function analysis of the
interaction between mCox11, LD of RanBP2, and subdomains
thereof, with quantitative yeast two-hybrid assays [32], showed
optimal interaction between the intact LD and Cox11
proteins (Figure 1C). Pull-down assays of retinal extracts with
glutathione S-transferase (GST)-LD precipitates a sodium
dodecyl sulfate-resistant dimer isoform of Cox11 (Figure 1D,
top panel), which does not bind to GST-LDZIP alone. In
addition to Cox11, we also found that other mitochondrial
components such as the outer membrane-associated protein,
HKI [33] (Figure 1D, bottom panel) and mHsp70 (unpub-
Figure 1. The LD of RanBP2 Interacts with Cox11 and HKI
(A) Primary structure of RanBP2 and its structural/functional domains. The N-terminal LD of RanBP2 is underlined.
(B) Sequence alignment of murine and yeast Cox11. The yeast Cox11 C- and N-terminal domains are poorly conserved. Arrow and solid line denote the
predicted mitochondrial cleavage site and membrane-spanning domain. The dotted and dashed lines above the aligned sequences represent,
respectively, Cox11-N and Cox11-C constructs shown in Figure 1C.
(C) Structure-function analysis of the interaction between the LD of RanBP2 and Cox11. Optimal interaction between the LD and Cox11 occurred in the
presence of constructs comprising both the complete LD and Cox11. Although removal of the cytosolic N-terminal (Cox11-C) significantly decreased the
interaction with LD, the mitochondrial intermembrane domain of Cox11 (Cox11-C) together with the C-terminal half of LD (LD-C) retained most of the
interaction activity. LD-N and LD-C ended and began with the leucine zipper domain of RanBP2. White and black bars denote b-galactosidase activity
and growth rates in selective growth medium, respectively. Results shown represent the mean 6 SD, n ¼ 3.
(D) GST pull-down assays with the LD of RanBP2 and its leucine zipper domain and retinal extracts. The LD, but not the leucine zipper domain of
RanBP2, associate with Cox11 (top panel, lane 1) and HKI (bottom panel, lane 1).
(E) Coimmunoprecipitation of RanBP2 with antibodies against its molecular partners shows that RanBP2 forms a complex in vivo with HKI (lanes 1 and
2), mHsp70 (lane 3), and Cox11 (lane 4). Lanes 5, 6, and 7 are control immunoprecipitation reactions with different antibodies against the RanBP2
domains, KBD, ZnF, and XAFXFG of nucleoporins.
(F) Reciprocal coimmunoprecipitation of HKI with antibodies against RanBP2 (used and shown in (E)).
(G) Reconstitution pull-down assays with purified LD and increasing concentrations of native (top panel), denatured (middle panel), and partially
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Synopsis
The Ran-binding protein 2 (RanBP2) is a large protein with several
domains. Although several protein partners were found to interact
with selective domains of RanBP2, none to this date were found
toward its large leucine-rich domain (LD). Cell-based experiments
support several roles of RanBP2 in cell function, such as the
production of functional proteins, control of protein trafficking
between the nuclear and cytosol compartments, and control of
multiple facets underlying cell division. Still, the genetic and
physiological implications of the interactions between RanBP2 and
its partners and of the function of RanBP2 in a whole-animal model
remain elusive. The authors report the identification of two novel
mitochondrial partners of the LD of RanBP2, Cox11 and hexokinase
type I (HKI); and with multidisciplinary approaches probe the role of
RanBP2 and its LD on Cox11, HKI, and functions allied to these. The
authors found that RanBP2 exhibits chaperone activity toward HKI
and Cox11. RanBP2 and Cox11 profoundly modulate HKI activity.
Moreover, partial loss-of-function of RanBP2 in a mouse model
induces deficits in growth rates and breakdown of glucose,
promotes the down-regulation of HKI and ATP levels selectively in
the central nervous system, and impairs visual function. These
findings support a critical role of RanBP2 and its partners in
metabolic processes and allied disease states.denatured (bottom panel) Cox11, respectively, in the absence and presence of denaturating agent, GnHCl and chaotropic agent, urea. Folding
intermediates (lower panel) of Cox11 exhibit the highest binding activity toward the LD of RanBP2.
(H) Similar experiments as in (G) but in the presence of native Cox11 expressed in the absence (top panel) or presence (bottom panel) of CuSO4. The
mature isoform of the metallochaperone has an increased affinity toward the LD of RanBP2. LD, leucine-rich domain; LZ, leucine zipper domain; RBD1–4,
Ran-binding domains 1–4; ZnF, zinc finger cluster domain; KBD, kinesin (KIF5B/KIF5C)-binding domain; CLD, cyclophilin-like domain; IR, internal repeat
domain; CY, cyclophilin domain.
DOI: 10.1371/journal.pgen.0020177.g001
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RanBP2 Modulation of Glucose Catabolismlished data), associated with LD of RanBP2. This association
was highly speciﬁc toward the HKI isoform, because HKII,
HKIII, and glucokinase did not interact with the LD of
RanBP2 (unpublished data). The interaction of Cox11, HKI,
and mHsp70 with RanBP2 occurred in vivo in retinal extracts,
since antibodies against these and RanBP2 coimmunopreci-
pitated RanBP2 (Figure 1E) and HKI (Figure 1F), respectively,
and these interactions were observed across different tissues
(Figure S1). Since RanBP2 exhibits chaperone activity, we
assessed whether the interaction between the LD of RanBP2
and Cox11 was direct and the chaperone activity of LD
toward folding species of Cox11. Reconstitution binding
assays were carried out between puriﬁed LD and Cox11, fully
and partially denatured with GnHCl and urea, respectively,
and native Cox11 (Figure 1G and 1H). Partial denatured
Cox11 exhibits signiﬁcantly higher and concentration-de-
pendent binding afﬁnity toward LD compared with the native
and fully denatured Cox11 (Figure 1G). In addition, native
Cox11 puriﬁed upon expression in the presence of CuSO4 (a
prosthetic group tightly bound to Cox11) [31], shows
signiﬁcantly higher binding activity toward the LD of
RanBP2, than in the absence of CuSO4 (Figure 1H).
Cox 11 Inhibits HKI Activity and the LD of RanBP2
Reverses the Inhibition of Cox11 over HKI
To probe whether the interaction of Cox11 and HKI with
the LD of RanBP2 modulates the enzymatic activity of HKI,
we ﬁrst examined the effect of increasing concentrations of
Cox11 on the initial rates of HKI enzymatic activity (Figure
2A). Cox11 strongly inhibits HKI activity in a concentration-
dependent fashion, and at ;15 nM of Cox11, HKI activity
could not be recorded (Figure 2A). Cox11 behaves as a partial
noncompetitive inhibitor of HKI by affecting the Vmax of HKI
for glucose (Figure 2B). Then, we evaluated the effect of the
LD of RanBP2 on the HK activity in the presence of a ﬁxed
inhibitory concentration of Cox11, saturating concentration
of glucose substrate, and increasing concentrations of LD. As
shown in Figure 2C, the LD domain sharply reversed the
inhibitory effect of Cox11 on HKI activity in a concentration-
dependent manner, but under saturating (and stochiometric)
amounts of LD, the velocity of the reaction did not reach that
observed for HKI activity in the absence of Cox11 (Figure
2A), suggesting the LD by itself may also have an effect on
HKI activity. Indeed, a saturating concentration of LD
reduced the Vmax but not the Km of HKI (Figure 2D) by
;20% under similar conditions.
RanBP2 Colocalizes with HK1, Cox11, and mHsp70 in the
Retina and Cultured Neurons
In addition to its presence at the vicinity of NPCs, we have
shown previously that RanBP2 is localized to and abundant in
the mitochondria-rich ellipsoid subcellular compartment of
photosensory (photoreceptor) neurons of the retina [19]. We
extended the subcellular colocalization studies on RanBP2
and its novel partners by immunocytochemistry to determine
if RanBP2, Cox11, HKI, and mHsp70 colocalize in hippo-
campal neurons (Figure 3A–3C), cerebral cortex neurons
(Figure 3D–3F), ellipsoid (mitochondria-rich) subcellular
compartments of photosensory neurons of the retina (Figure
3G–3O), and dissociated primary glia and neuron cultures
from the brain (Figure 3P–3Z). Double immunostaining with
antibodies against these proteins showed that they colocalize
to the mitochondria (Figure 3A–3Z).
Haploinsufficiency of RanBP2 Causes Decreased Levels of
HKI and Partial Mislocalization of HKI
To determine the physiological implications of the
interaction between RanBP2 and HKI (and other partners),
we employed a murine embryonic stem 129Ola cell line with a
targeted RanBP2 locus produced by gene-trapping to
produce stable inbred (coisogenic) and mixed background
lines, respectively (Figure 4A and 4B). Genotyping of 299 F2
offspring revealed a RanBP2
þ/þ:RanBP2
þ/ :RanBP2
 /  distribu-
tion (89:210:0) that deviated from the expected Mendelian
ratio and supports that the RanBP2
 /  mice were embryoni-
cally lethal. E12.5 embryos show strong expression of RanBP2
in the optic vesicle and throughout much of the embryo,
which had no apparent developmental abnormalities (Figure
4C). In agreement with previous immunocytochemistry
analysis [19], the RanBP2 gene is expressed across mature
retinal neurons, but expression in ganglion cells of the adult
retina was extremely strong (Figure 4D and 4E).
In light of the association in vivo of RanBP2 with Cox11
and HKI (Figures 1 and 3), profound in vitro modulation of
HKI enzymatic activity by RanBP2 and Cox11 (Figure 2), and
Figure 2. Effect of Cox11 and RanBP2 on HKI Activity
(A) Saturation kinetics, rate versus glucose of HKI (0.24 lg) in the absence
(solid circles) and presence of Cox11 (open circles, 0.25 nM; solid
triangles, 7.5 nM). The activity of HKI decreases with increasing
concentrations of Cox11. No measurable HKI activity was recorded in
the presence of 15 nM of Cox11 (unpublished data).
(B) Hanes-Wolf plot of (A) (1/rate versus glucose) in the absence and
presence of fixed concentrations of Cox11. Linearity of reciprocal plots
also supported the hyperbolic behavior of the reactions (unpublished
data). Cox11 behaves as a noncompetitive inhibitor of HKI by reducing
the Vmax of HKI but not its Km toward glucose.
(C) HKI rate is plotted as a function of LD concentration at saturating
glucose and fixed Cox11 (7.5 nM) concentrations. Note that increasing
concentrations of the LD of RanBP2 reverse the inhibition of HKI activity
by Cox11. A half-maximal effect of the LD of RanBP2 on HKI activity in
the presence of 7.5 nM of Cox11 was observed at a concentration of
;0.05 nM of LD.
(D) Rate versus glucose plot in the absence and presence of the LD of
RanBP2. At a saturating concentration of the LD of RanBP2 (3.75 nM), the
HKI activity was reduced by about 20%. v, rate; S, glucose.
DOI: 10.1371/journal.pgen.0020177.g002
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RanBP2 Modulation of Glucose Catabolismthe critical role of HKI in catalyzing a rate-limiting step of
glycolysis, we probed whether RanBP2
þ/  mice presented
disturbances in HKI, Cox11, and energy homeostasis. Mono-
allelic expression of RanBP2 does not affect the number of
NPCs and their distribution in hippocampal neurons (Figure
5A, unpublished data), but it led to consistent lower
expression of RanBP2 by more than 50% in the CNS (brain
and retina) in 129Ola (Figure 5B–5D), but not in C57BL/6J/
129Ola backgrounds (unpublished data). Hence, we focused
our analysis on the inbred RanBP2
þ/  129Ola mouse line.
Although the levels of RanBP2 were decreased in the retina,
brain, and hippocampus of RanBP2
þ/ mice by ;50%–60%
(Figure 5B and 5C), the levels of others nucleoporins, Nup153
and Nup62, and mHsp70 and Cox11, remained unchanged
(Figure 5B, unpublished data). In addition, we observed a
strong decrease of the levels of HKI (3- to 4-fold) (Figure 5B
and 5C). This decrease was selective to the CNS, since HKI
levels remained largely unaffected in the skeletal muscle,
spleen, and liver (Figure 5D). Because HKI plays a key role in
the production of energy intermediate substrates and HKI is
virtually the sole HK isoform expressed in the CNS [33,34], we
probed the impact of HKI and RanBP2 reduction in the levels
of ATP. As shown in Figure 5E, there was signiﬁcant and
concordant reduction in levels of ATP in the CNS (brain and
retina), but not in non-neuronal tissues. Finally, we also
observed partial and selective delocalization of HKI, but not
of Cox11, from the ellipsoid (mitochondria-rich) to the
adjacent myoid subcellular compartment of rod photo-
sensory neurons (Figure S2A–S2E). This was also accompa-
nied by reduced HKI levels in the inner retina, in particular
in the inner plexiform (synaptic) layer (Figure S2A–S2E).
Metabolic Disturbances Caused by Haploinsufficiency of
RanBP2
The growth rates of inbred RanBP2
þ/  mice on high-fat
(;10% fat) diet were signiﬁcantly slower than RanBP2
þ/þmice
(Figure 6A). Beginning at around 4 mo of age, RanBP2
þ/ mice
exhibit a signiﬁcant slower gain in body mass than wild-type
Figure 3. Localization of RanBP2 and Its LD Molecular Partners
(A–F) are thin cryosections of an area of the hipocampus (CA1 neurons) and cerebral cortex, respectively, immunostained against HKI (A and D), RanBP2
(B and E), and merged images thereof (C and F). Note that while RanBP2 and HKI are widely expressed among and colocalize to hippocampal neurons
(C), HKI expression and localization with RanBP2 is restricted to a subset of cortical neurons (likely interneurons) (F). Images of the distal region of
bovine retinal cryosections comprising part of the nuclear layer of photoreceptor neurons and their inner (myoid and ellipsoid) segment compartment
(G–O) are immunostained against mHsp70 (G) and RanBP2 (H), mHsp70 (J) and Cox11 (K), HKI (M) and Cox11 (N), and merged images thereof (I–O). Note
the prominent localization of RanBP2, mHsp70, and Cox11 at the mitochondria-rich ellipsoid compartment of photoreceptors and the colocalization of
RanBP2 and Cox11 with mHsp70 (I and L), while HKI colocalization with Cox11 was limited to restricted foci (R, arrowheads). High-resolution images of
dissociated primary cerebral neurons and glial cells confirmed that the colocalization of HKI and Cox11 was highly restricted (P–R), while RanBP2
extensively colocalized with HKI (S–U) and mHsp70 (V–Z). Scale bars in A–O and P–Z are 40 and 10 lm, respectively. ONL, outer nuclear layer.
DOI: 10.1371/journal.pgen.0020177.g003
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þ/  inbred mice
presented deﬁcits in body mass that were erased by changing
the genetic background to a mixed C57BL/6J/129Ola (Figure
6B). Food consumption did not account for the body weight
differences observed (Figure 6C).
HKI in the CNS (brain and retina) accounts virtually for all
expression of HK isozymes and glucose utilization in the CNS
[33,34]. Moreover, glucose is the sole reliance source of
energy in the CNS under normal conditions, the CNS lacks
glucose storage sources, and despite the disproportionate
mass of the CNS to the rest of the body, the CNS consumes
daily about 60% of the body’s glucose and 25% of the total
oxygen [35,36]. To determine the impact of RanBP2 hap-
loinsufﬁciency on the utilization, formation, and uptake of
glucose, we carried out several physiological assays. In
contrast to mice placed on a normal chow diet (;5% fat;
unpublished data), RanBP2
þ/ mice on a higher fat diet (;10%
fat) performed signiﬁcantly worse in the glucose tolerance
test beginning at 6 mo of age (Figure 7A and 7B), thus
supporting that the RanBP2
þ/  mice exhibited a deﬁcit in
glucose clearance. This deﬁcit was rescued in RanBP2
þ/  mice
of mixed C57BL/6J/129Ola background (Figure S3). Glucose
clearance was not affected due to a disturbance in insulin-
mediated glucose uptake (Figure 7C). Then, we probed
whether RanBP2 induces impairment of gluconeogenesis,
which could contribute to the pathophysiological production
and clearance of glucose. To this end, the administration of
the gluconeogenic substrate precursor, pyruvate (pyruvate
tolerance test), showed that there was no difference in glucose
production in RanBP2
þ/  mice (Figure 7D). Hence, partial
loss-of-function of RanBP2 had no impact on the gluconeo-
genesis pathway. However, upon glucose production (15 min),
the clearance rates of glucose were again signiﬁcantly slower
in RanBP2
þ/  than in RanBP2
þ/þ mice (Figure 7D), conﬁrming
an impairment in glucose breakdown.
Figure 4. Insertion Mutagenesis of the Murine RanBP2 Gene
(A) Diagram of the genomic region of RanBP2 disrupted by insertion trap mutagenesis with a bicistronic reporter vector between exon 1 and 2. The
bicistronic transcript produces two proteins under regulation of RanBP2. Upon splicing of RanBP2, a fusion between exon 1 and b-geo (a fusion
between the b-gal and neo genes) is generated, while human placental alkaline phophatase (PLAP) is independently translated using the internal
ribosome entry site. Consistent with previous studies, the expression of the former is directed to cell bodies, while expression of the latter is targeted to
the axonal processes [67,68]. Transcriptional 59 RACE analysis detects a fusion between exon 1 and b-geo.
(B) Southern analysis of the RanBP2 locus of wild-type and heterozygous genomic DNA of tails of F1 mice digested with PpuMI (left panel) and HindIII
(right panel) with probes at the 39 (left panel) and 59 (right panel) flanking regions of the insertion breakpoint. Q1 is a cosmid containing the RanBP2
gene up to exon 20 [4].
(C) Lateroventral view of a whole-mount stain of a ;12.5 dpc heterozygous embryo for PLAP and b-gal (inset picture) activities. Although PLAP was
broadly expressed (e.g., somites, limbs, and CNS), the PLAP and b-Gal (inset picture) expression was particularly high in the optic vesicle (arrow). X-gal
single (D) and combined staining with PLAP (E) of a retinal section of a 3-mo-old RanBP2
þ/  mouse. Consistent with previous immunocytochemistry
studies, b-Gal activity is detected in the neuroretinal bodies and inner segment compartment of photoreceptors with conspicuously strong expression
in ganglion cells. PLAP expression is found throughout the plexiform/synaptic layers and outer segment of photoreceptors (E). GC, ganglion cell; PLAP,
human placental alkaline phophatase; ROS, rod outer segment; RIS, rod inner segment; ONL, outer nuclear layer; OPL, outer plexiform (synaptic) layer;
INL, inner nuclear layer; IPL, inner plexiform (synaptic) layer; GC, ganglion cell layer.
DOI: 10.1371/journal.pgen.0020177.g004
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RanBP2 Modulation of Glucose CatabolismHaploinsufficiency of RanBP2 Causes Deficits in the
Electrophysiological Output of Receptoral and
Postreceptoral Retinal Neurons
In light of the prominent expression of RanBP2 and HKI in
retinal neurons [1,19], the vital dependence of the neuronal
retina (and brain) on glucose as the main substrate source for
energy production, and the determinant impact of metabolic
disorders, such as diabetes, in retinal function (e.g., diabetic
retinopathy) [37], we probed the impact of deﬁcits in RanBP2,
HKI, and ATP, on the electrophysiological responses of
subclasses (rod and cone) photoreceptor and postreceptor
retinal neurons of RanBP2
þ/  and in RanBP2
þ/þ mice. The
scotopic (dark-adapted) responses mediated by the rod
photoreceptor pathway at low-stimulus intensities and mixed
rod and cone pathways at high-stimulus intensities were
substantially reduced in RanBP2
þ/  mice (Figure 8A). The
differences in the photopic (light-adapted) responses, ini-
tiated by cone photoreceptors, which make up 3% of the
photosensory neurons in the mouse retina [38], were less
obvious but still exhibited a trend toward reduced amplitudes
across a range of increasing light stimulus intensities (Figure
8B). The reduction in the scotopic responses included
decreases in both b-wave (Figure 8C) and a-wave (Figure 8D)
amplitudes mediated by postreceptoral and receptoral
neurons, respectively. Postreceptoral second-order neuron
responses, represented by the b-wave, tended to be more
consistently and substantially reduced than the a-waves,
which directly reﬂect photoreceptor activity. Since second-
order neuron responses depend on input from photo-
receptors, this suggests that reduced b-wave amplitudes are
the result of the accumulation of decreases in the light
response of both photoreceptors and postreceptoral neurons.
Anesthetics, particularly ketamine, can cause sustained
elevation of glucose in mice, which in turn affects electro-
retinogram responses [39]. Thus, we were concerned that
differences in electroretinogram amplitudes between
RanBP2
þ/  and RanBP2
þ/þ may reﬂect differences in glucose
level changes in response to anesthesia. However, we found
no signiﬁcant differences in glucose levels measured before
and every 15 min during 75 min of anesthesia (n ¼ 4–5).
Glucose rose at the same rate and reached a maximum of
approximately 3.3 times the pre-anesthesia level in both
genotypes (unpublished data).
Discussion
Our ﬁndings support that RanBP2 plays a determinant role
in modulating glucose and energy homeostasis. The data
support that Cox1 and HKI are novel partners in vivo for the
large LD of RanBP2 (Figures 1 and 2). The LD of RanBP2
exhibits chaperone activity toward folding intermediates of
Figure 5. Haploinsufficiency of RanBP2 Causes a Decrease in HKI Protein and ATP Levels
(A) Quantitative analysis of NPCs in dissociated hippocampal neurons of wild-type (þ/þ) and heterozygote (þ/ ) mice upon immunostaining with
mAb414. No difference in the density of NPCs (3–4 NPC/lm
2) at the nuclear envelope was found between RanBP2
þ/þ and RanBP2
þ/  mice.
(B) Immunoblots with anti-RanBP2/Nup153/Nup62 (mAb414),  HKI,  mHsp70, and  Cox11 antibodies of retinal (top panel) and hippocampal
homogenates ofþ/þandþ/ mice. In comparison to RanBP2
þ/þ, RanBP2
þ/ mice exhibit a reduction in the expression levels of RanBP2 and HKI but not
of other proteins.
(C) Quantitative analysis of relative protein expression levels of RanBP2, Cox11, HKI, and mHsp70 in the hippocampus of RanBP2
þ/þand RanBP2
þ/ mice.
There is ;2- and 4-fold reduction of RanBP2 and HKI in heterozygote mice.
(D) The level of HKI is reduced in the brain but not in other non-neuronal tissues tested (muscle, spleen, and liver).
(E) The total ATP level is reduced in the CNS tissues (brain and retina) but not in non-neuronal tissues tested (e.g., spleen).
DOI: 10.1371/journal.pgen.0020177.g005
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RanBP2 Modulation of Glucose CatabolismCox11, and possibly, the mature HKI (Figure 1). Cox11
inhibits noncompetitively the activity of HKI with ;2–3
molecules of Cox11 (assuming formation of Cox11 dimer)
required to inhibit completely the activity of a molecule of
HKI (Figure 2A and 2B). Cox11 sequesters HKI by binding to
HKI at a site that is distinct from the active site and
effectively reduces the availability of [HKI]tot for catalysis.
This is reﬂected by a reduction of the Vmax of HKI without
signiﬁcantly affecting the Km of the active site of HKI toward
glucose (Figure 2A and 2B). The inhibitory property of Cox11
over HKI is suppressed by RanBP2 (Figure 2C), which by itself
has a weak but signiﬁcant inhibitory activity over HKI (Figure
2D). The sub-stochiometry effect of the LD of RanBP2 over
the inhibition of HKI by Cox11 supports that a LD-depend-
ent chaperonin-like mechanism underlies the suppression of
Cox11-dependent inhibition of HKI by RanBP2, and that
RanBP2 acts as a molecular ‘‘buffer’’ over HK1 and Cox11
activities. The partial loss of the RanBP2 chaperone activity
in RanBP2
þ/ mice also leads to deﬁcits in the sequestration of
HKI in the ellipsoid compartment of photosensory neurons.
This possibly underlies the mistargeting of HKI to the myoid
compartment of these neurons (Figure S2). The data support
that the ultimate pathophysiological outcome in HKI, caused
by a reduction in RanBP2 levels and its chaperone activity, is
the selective degradation of HKI as reﬂected by the reduced
levels of HKI (and ATP) but not of other mitochondrial and
NPC components (Figure 5). Through this process, it is also
possible that deﬁcits in RanBP2 cause a disturbance in the
equilibrium between Cox11, HK1, and RanBP2 by leading to
an increase of the inhibitory activity of Cox11 over HKI that
promotes the uncoupling of the interaction of HKI from
RanBP2, ultimately causing HKI degradation. Regardless,
lower levels of HKI likely contribute to the decreased levels in
ATP, slower growth rates, and diminished ability to metab-
olize glucose of RanBP2
þ/  mice (Figures 5–7). As discussed
subsequently, the ATP deﬁcits in the retina likely account for
the reduced electrophysiological responses of retinal neurons
(Figure 8).
Various domains of RanBP2 have been previously impli-
cated with a chaperone role in the cell. These include the
enhancement of the biogenesis of red/green opsin by the
combination of the RBD4-CY domains [6,7] and the stabiliza-
tion by the Ran-binding domains of RanBP2 of the guanosine
triphosphate-bound conformational state of RanGTPase and
interaction of Ran with importin-b [11,40,41]. The data
herein show that the multi-chaperone role of RanBP2 extends
also to its LD in light of its ability to associate to distinct
folding species of Cox11 and to prevent HKI from being
degraded. This chaperone function is likely to be comple-
mented by other partners of RanBP2 with similar and
pleiotropic functions. For example, the combination of the
CLD of RanBP2 with several subunits of the 19S cap of the
proteasome [14], and of its neighboring internal repeat,
W1W2/IR with the E3-ubiquitin ligase, parkin [20], and the E2
SUMO-1-conjugating protein, Ubc9 [15] may contribute to
the down-regulation of HKI by 26S proteasome-mediated
proteolysis and modulation of the molecular and subcellular
partitioning of these partners. In this regard, it will be
interesting to probe whether parkin also causes deﬁcits in
HKI in dopaminergic neurons, since parkin was reported to
modulate RanBP2 turnover [20], and parkin loss-of-function
also causes energy and growth deﬁcits [26–29,42]. These data
add a new dimension to the complexity of the regulation of
the glycolytic pathway, in particular in the CNS, where
glycolysis plays a major role in supplying energy and where
t h ep r o t e a s o m em a c h i n e r ym a yp l a yac r i t i c a lr o l ei n
modulating components of the energy supply machinery
[43]. This is further evidenced by the presence of genetic
modiﬁers in RanBP2
þ/  mice on a mixed genetic background
that compensates for deﬁcits in RanBP2 and deregulation of
its partners in glucose/energy homeostasis as observed in the
coisogenic line. The presence of such compensatory mecha-
nisms is also supported by the identiﬁcation of a quantitative
Figure 6. RanBP2
þ/  Mice on High-Fat Diet Exhibit Deficits in Growth
(A) In comparison to wild-type mice, RanBP2
þ/ mice show slower growth
rates beginning at 4 mo of age (arrow), and the difference in body
weight between these is maintained afterward. Note that RanBP2þ/ 
mice lack the growth spur observed in wild-type mice between 3 and 4
mo of age.
(B) In comparison to inbred RanBP2
þ/ mice (129Ola genetic background),
the difference in body weight between RanBP2
þ/þ and RanBP2
þ/  mice is
masked upon placing these on a mixed 129Ola/C57Bl6 genetic
background.
(C) RanBP2
þ/þ and RanBP2
þ/ inbred mice exhibit similar rates of food
consumption. Mice in (A), (B), and (C) were placed on a high-fat diet since
birth (n ¼ 5).
DOI: 10.1371/journal.pgen.0020177.g006
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RanBP2 Modulation of Glucose CatabolismFigure 7. Metabolic Phenotypes of RanBP2
þ/  Inbred Mice on High-Fat Diet
(A) 3-mo-old inbred RanBP2
þ/  mice (n ¼ 5) have normal glucose clearance rates upon glucose challenge and overnight fasting.
(B) In contrast, 6-mo-old inbred RanBP2
þ/  mice (n ¼ 5) have significantly decreased glucose clearance rates upon glucose challenge and overnight
fasting.
(C) Fasted6-to8-mo-oldRanBP2
þ/þandRanBP2
þ/ micehavenodifferencein insulin-mediatedglucoseuptakeas assayedbyinsulintolerancetest(n¼5).
(D) Pyruvate tolerance test shows normal rise in glucose but decreased glucose clearance between inbred RanBP2
þ/þ and RanBP2
þ/  mice (n ¼ 5).
DOI: 10.1371/journal.pgen.0020177.g007
Figure 8. Electroretinograms from 6-Mo-Old RanBP2
þ/ and RanBP2
þ/þ Inbred Mice Showing Photoreceptor and Postreceptor Neuron Electro-
physiological Response Phenotypes
(A) Scotopic (dark-adapted) responses from RanBP2
þ/  mice to light stimuli of increasing intensity, beginning at threshold, have reduced amplitudes
compared to those observed in RanBP2
þ/þmice. The three lower intensities represent responses generated in the rod photoreceptor neuronal pathway.
The upper intensities are comprised of responses generated in both the rod and cone pathways.
(B) Photopic (light-adapted, cone photoreceptor pathway) responses of RanBP2
þ/  mice to increasing light stimulus intensities also exhibited reduced
amplitudes compared to those observed in RanBP2
þ/þ mice.
(C) Average 6 SE (n ¼ 9) scotopic b-wave amplitudes from RanBP2
þ/  (open circles) and RanBP2
þ/þ (filled squares) mice representing postreceptoral
neuron function. (Note: log amplitude scale.)
(D) Average 6 SE (n ¼ 5) scotopic a-wave amplitudes, representing photoreceptor function, for RanBP2
þ/  and RanBP2
þ/þ mice in response to bright
flashes. Amplitudes of responses from RanBP2
þ/  mice were lower over the entire range of stimulus intensities for both b- and a-waves. Asterisks
represent significant differences between the groups (Student’s t test, p , 0.05). Statistical significance was found across all intensities for b-wave
amplitudes (2-way ANOVA, p , 0.0001), but not for the a-wave.
DOI: 10.1371/journal.pgen.0020177.g008
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RanBP2 Modulation of Glucose Catabolismtrait locus, which encompasses RanBP2, and modiﬁes the
expression of diabetes-related phenotypes [44].
The data herein show tissues with a decrease of RanBP2
and HKI levels mirror a reduction in the ATP levels. Since the
constitutive Na
þ/K
þ ATPase pump and the ATP-dependent
conversion of glutamine to glutamate (both fundamental to
maintain the electrical activity in the CNS) consumes the vast
majority of the energy produced by the CNS [45–47], this
likely underlies the suppression of the electrophysiological
output responses of retinal neurons (Figure 8). Moreover,
deﬁcits in HKI may lead to intracellular hyperglycemia in the
CNS, promote sorbitol-induced osmotic stress, and compro-
mise further the ATPase-dependent Na
þ/K
þ pump activity
[48–50]. This may be exacerbated by a decrease of ATP, since
the activity of HKI is also stimulated by ATP [51]. The
cumulative effects of a reduction in ATP and intracellular
hyperglycemia are known to act synergistically and modulate
the electrophysiological properties of neuronal activity.
Figure 9 integrates in a model these variables and implica-
tions of the data presented herein. Still, other bona ﬁde
RanBP2 partners previously identiﬁed and described in the
Introduction also become strong candidates to play a role in
energy homeostasis. For example, the unfolding and chaper-
one activity of components of the 19S cap of the proteasome
may be modulated by the CLD of RanBP2 [14] and contribute
to the selective HKI (and other substrates) degradation [43],
while association of nuclear import receptor, importin-b with
the Ran-binding domains of RanBP2 [10,11], may mediate the
nuclear translocation of multifunctional substrates, such as
glyceraldehyde-3-phosphate dehydrogenase. This trafﬁcking
process is selectively inhibited by the neuroprotective drug,
R-(-)-deprenyl and derivates thereof, and are often employed
to treat Parkinson disease [52–57]. Hence, RanBP2 and its
partners emerge as key players and target genes in mediating
neuropathophysiological mechanisms implicated in various
genetic and environmental lesions to the CNS, as in patients
with Parkinson, diabetes with insulin-resistance, and other
neuropathies and neurodegenerative diseases, often linked to
aging manifestations. To this effect, the RanBP2 mouse model
will serve as a unique genetic tool to probe selective, multiple
and novel pathways, which may have not been anticipated to
be linked to metabolic processes and allied pathophysiolog-
ical states.
Finally, RanBP2 appears to join other nucleoporins, such as
Nup96 [58], in novel physiological functions that are vital for
complex organisms and that were not anticipated from cell-
based studies. The reduced expression of these proteins in
whole-animal models generates phenotypes that are tissue-
restricted and more importantly, do not seem to recapitulate
phenotypes observed with knockdown experiments in cell-
based culture assays. For example, short interfering RNA-
mediated knockdown of RanBP2 [9] and members of the
Nup107-Nup160 complex [59–61] have shown, respectively, to
cause mitotic arrest and disruption of nuclear pore assembly
and deﬁcits in mRNA export in cell culture. Yet, haploinsuf-
ﬁciency of RanBP2 (this work) and Nup96 [58] predominantly
produce, instead, CNS-restricted deﬁcits in energy metabo-
lism and alterations in the immune system linked to the
down-regulation of interferon-b-regulated proteins and
increased susceptibility of viral infection, respectively. While
these apparent outcome disparities among experimental
systems remain unclear, they could potentially result from
variations in redundancies and compensatory mechanisms
inherent to each experimental system. Regardless, these
genetic and whole-animal models set the stage to probe
novel molecular pathways in various physiological and
genetic contexts, and provide also a link to pathophysiolog-
ical processes underlying several human diseases.
Materials and Methods
Yeast two-hybrid screening and assays. The LD of human RanBP2
(residues 62–711) was subcloned in-frame into the GAL4 DNA-
binding domain of bait vector, pBUTE (a kanamycin-resistant version
of GAL4 bait vector pGBDUC1) [62] and HybriZAP pBD-GAL4 vector
(Stratagene, La Jolla, California, United States). The former was used
to screen ;18 million clones via mating from murine 9- to 10-d-old
embryo and brain cDNA libraries at the Molecular Interaction
Facility (MIF), University of Wisconsin, Madison, Wisconsin. The
latter was used to screen via transformation of ;5 million clones
from bovine retinal cDNA libraries [32]. The screens generated six
clones. One and two in-frame clones were independently isolated
from the embryonic and adult brain libraries, respectively, and the
interactions were validated. The three clones encoded Cox11.
Interactions between Cox11, LD, and subdomains thereof were
quantiﬁed by liquid b-galactosidase (Applied Biosystems, Foster City,
California, United States) and growth assays [63]. The maximum
speciﬁc growth speed (lmax) was determined by calculating lmax ¼
Figure 9. Model Depicting a Role of RanBP2 and Some of Its Partners in
Metabolic and Neuronal Function
RanBP2 interacts with Cox11 and HKI and the triad is in equilibrium
under normal physiological conditions. RanBP2 prevents the inhibition of
HKI by Cox11 and its degradation. The ultimate effect of RanBP2 on its
partners is the stimulation of the glycolytic pathway and production of
ATP. The glycolytic pathway is critical to fuel the constitutive Na
þ/K
þ-
ATPase pump to maintain the dark current between the inner and outer
segment compartments of photosensory neurons. A deficit (haploinsuf-
ficiency) in RanBP2 disturbs the equilibrium between RanBP2, HKI, and
Cox11. This pathophysiological event promotes the destabilization and
degradation of HKI and a decrease in ATP production required to
maintain the depolarization state neurons, and, hence, a reduction in the
response of receptoral and postreceptoral neurons. A reduction in ATP
levels also negatively modulates HKI activity/level. Decreased levels of
HKI promote intracellular hyperglycemia and activate stress kinases,
which modulate negatively the Na
þ/K
þ-ATPase pump by phosphoryla-
tion. Pathophysiological pathways promoted by RanBP2 haploinsuffi-
ciency are represented by dash lines. RIS, rod inner segment; ROS, rod
outer segment.
DOI: 10.1371/journal.pgen.0020177.g009
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RanBP2 Modulation of Glucose Catabolism(ln(xt)   ln(x0))/t, where xt is the OD600 of the culture at t ¼ t, x0 is the
OD600 at t ¼ 0 and t is the time between x0 and xt. Assays were
performed with three independent clones and three samples of each
clone, the results were averaged, and the standard deviations
calculated.
Site-directed and deletion mutagenesis and plasmid construction.
Deletion mutagenesis was carried out with pairs of primers against
domains of interest described in the ﬁgure legends. PCR products
were subcloned into pGEX-KG [64], HybriZAP pBD-GAL4 vector
(Stratagene), and pBUTE [62] vectors. GST-LDZIP alone comprised
residues 447–483 of human RanBP2.
GST pull-down and immunoprecipitation assays. CHAPS-solubi-
lized retinal extracts, expression, and puriﬁcation of GST-fused
constructs were prepared as previously described [65]. GST pull-
down assays were carried out with 0.5–2.2 lM of GST-fused proteins
[65]. Co-precipitates were resolved on SDS-PAGE and analyzed by
Western blot with antibodies described in the Results section.
Unfolded and partially denatured Cox11 were generated by incubat-
ing recombinant and native Cox11 overnight with 5.6 and 7 M
guanidine hydrochloride and urea, respectively. The Cox11 con-
formers were then diluted ;20-fold in CHAPS-binding buffer
containing GST-LD. Immunoprecipitation assays with 5 lgo f
antibody and Western blots (; 200–400 ng/ml of antibody) were
performed exactly as described previously [13].
Hexokinase I assay. Hexokinase I activity was determined
spectrophotometrically at 25 8C by the method of coupling the
glucose-6-phosphate production via glucose-6-phosphate dehydro-
genase with the change in the absorbance of NADPH at 340 nm and
as described by [66]. The reaction was started by the addition of
puriﬁed brain hexokinase I (0.24 lg) (gift from J. Wilson) to 1.0 ml of
reaction mixture containing 0.05 M Tris-HCl (pH 8.5), 7.4 mM MgCl2,
6.6 mM ATP, 0.65 mM NADP, 11.1 mM monothioglycerol, and 1 unit
of glucose 6-phosphate dehydrogenase. In the case of hexokinase
activity measured in the presence of Cox11 and LD, the puriﬁed HKI
was incubated with the recombinant proteins for 15 min at 4 8C
before measurement of the activity. The data were ﬁtted directly into
the Michaelis-Menten equation using SIGMAPLOT (SPSS Science).
Antibodies. Rabbit antisera were raised against the recombinant
murine Cox11 (residues 40–275) and afﬁnity-puriﬁed under non-
denaturing conditions (Stereogene) as previously described [13].
Cox11 antibodies were used at 200 ng/ml for Western analysis. The
monoclonal antibody Hsp70 was from Afﬁnity Bioreagents (Golden,
Colorado, United States) and antibodies against the KBD (JX2) and
ZnF domains of RanBP2 have been described [13,16]. Polyclonal and
monoclonal antibodies against Hexokinase I were provided by J.
Wilson. The mAb414 was purchased from Abcam (Cambridge,
Massachusetts, United States).
Immunocytochemistry and microscopy. Retina dissections, radial
cryosections (;6 lm), and immunohistochemistry procedures were
carried out as described elsewhere [19]. Brains from 3- to 5-mo-old
C57Bl/6 mice were ﬁxed overnight in 2% paraformaldehyde, infused
with 30% sucrose, and processed for cryosectioning. Primary brain
neurons and glial cells were prepared from the cerebral cortex. This
was macerated in the Hank’s Balanced Salt solution and triturated.
Primary cells were cultured in DMEM (GIBCO, San Diego,
California, United States) and collagen-coated 35-mm glass bottom
culture dishes (MatTek Corporation, Ashland, Maine) at 5% CO2/37
8C for ;2 d and processed for immunocytochemistry. Primary
antibodies were used at concentrations ;2.5–10 lg/ml. Alexa 488-
and Alexa 594-conjugated secondary antibodies (2.5 lg/ml) (Molec-
ular Probes) were used for visualization of proteins. Crossover of
ﬂuorescent probes, background, and autoﬂuorescence were found
to be negligible. Visualization of specimens and localization of
proteins were carried out by wide-ﬁeld epiﬂuorescence microscopy
on Nikon (Tokyo, Japan) E600 upright and TE2000U inverted
research microscopes equipped with similar Apochromat objectives.
Images with the Nikon E600 were acquired with a SPOT-RT digital
camera coupled to the microscope and driven by SPOT Imaging
v4.0 software (Diagnostic Instruments, Sterling Heights, Michigan,
United States). All images were captured at nonsaturating integra-
tion levels, 12-bit mono black/white, and then pseudo-colored.
Protein colocalization analysis was carried out on the Nikon
TE2000U microscope equipped with appropriate excitation and
emission ﬁlter wheels, cube ﬁlters, 100 W mercury light source,
Nomarski/DIC, and Plan Apochromat optics (1003,6 0 3, and 403 oil
objectives with NA of 1.4, 40 3LWD, and 20 3LWD objectives and
encoded motorized Z-Stage (Prior Scientiﬁc, Rockland, Maryland,
United States). Images with the inverted Nikon TE2000U micro-
scope were obtained using a CCD camera (CoolSNAP HQ; Roper
Scientiﬁc, Trenton, New Jersey, United States). Images acquired
under identical acquisition parameters were analyzed using Meta-
morph Software v6.2 (Universal Imaging, Glendale, Wisconsin,
United States). Whenever applicable, serial optical Z-stacks (20–30
focal planes at 100-nm intervals) were captured and computation-
ally processed by 3-D blind deconvolution methods with the same
software.
Generation of a mouse line with a disrupted RanBP2 locus and
histological analysis of trapped RanBP2 mice. A feeder-independent
mouse ES cell line derived from the 129P2/OlaHsd strain and
harboring a disrupted RanBP2 locus by insertion mutagenesis with
the gene trap vector, pGT0pfs [67,68] (generated by W. Skarnes), was
obtained from the Mutant Mouse Regional Resource Center (Uni-
versity of California Davis, Davis, California, United States). The gene
trap vector contains a promoterless neo-lacZ fusion gene with a splice
acceptor site at the 59 end followed by an internal ribosome entry site
(IRES) and the human placental alkaline phosphatase (PLAP)
reporter cassette. The RanBP2 129Ola ES line was injected into
C57BL/6J blastocysts and four male chimeras were generated. These
were bred into 129P2/OlaHsd (Harlan, Indianapolis, Indiana, United
States) and C57BL/6J (Jackson Laboratory, Bar Harbor, Maine, United
States) females. The two resulting and independent F1s lines, with
129P2/OlaHsd inbred and 129P2/OlaHsd/C57BL/6J mixed genetic
backgrounds, were tested for germline transmission by PCR and
Southern blot analysis of tail genomic DNA. b-gal and PLAP activities
in whole mount embryos and retinal sections were detected,
respectively, by incubation with 5-bromo-4-chloro-3-indolyl b-D-
galactopyranoside and AP staining buffer (0.1 mg/ml 5-bromo-4-
chloro-3-indolyl phosphate, 1 mg/ml nitroblue tetrazolium in 100 mM
Tris-HCl (pH 9.5), 100 mM NaCl, 5 mM MgCl2) as described elsewhere
[67,68].
Western blot and quantitation analysis of protein expression and
ATP levels. Homogenates and detergent solubilized extracts of tissues
and immunoblots were prepared as described elsewhere [69].
Quantitation of immunoblot bands calibrated against internal
marker bands, such as mHsp70 and Nup153, was carried out with
Gel Pro Analyzer (MediaCybernetics, San Diego, California, United
States). For determination of ATP levels, freshly dissected and ﬂash-
frozen tissues were homogenized in 2.5% trichloroacetic acid (TCA),
neutralized, and diluted to a ﬁnal concentration of 0.1% with Tris-
Acetate (pH 7.75). ATP measurements were carried out with the
ENLITEN ATP Assay System Bioluminescence Detection Kit for ATP
(Promega, Madison, Wisconsin, United States) as per the manufac-
turer’s instruction in SpectraMax-M5 (Molecular Devices, Sunnyvale,
California, United States). Protein concentration was measured by
the BCA method (BioRad, Hercules, California, United States) using
BSA as a standard.
Metabolic assays. Two groups of male mice were kept under
separatedietsincegestationorbirth.Onegroupwasfedwithanormal
chow diet (PicoLab Rodent Diet 20  5053; LabDiet, Richmond,
Indiana, United States), while the other was placed on a higher energy
and fat diet (PicoLab Mouse Diet 20  5058; LabDiet). Glucose
tolerance test was performed on overnight-fasted mice injected
intraperitoneally with 2 g of glucose per kg of body weight. Venous
blood glucose values were determined at immediately before (0 min),
and 15, 30, 60, and 120 min after the injection with an automatic
glucose monitor instrument (One Touch Ultra, Lifescan). Insulin
tolerance test was performed the same way as that described for the
glucosetolerancetestwiththeexceptionthathumaninsulin(0.75U/kg
of body mass) was injected intraperitoneally in non-fasted mice.
Pyruvate challenge test was performed the same way as that described
for the glucose tolerance test with the exception that pyruvate
dissolved in saline (2 g/kg of body mass) was injected intraperitoneally
in overnight-fasted mice.
Electroretinography. Five ;6-mo-old male RanBP2
þ/þ and
RanBP2
þ/  mice in 129ola background were kept in dim cyclic light
(10 lux) for 2 wk before electroretinographic responses were
recorded. The mice were anesthetized intraperitoneally with ket-
amine (80 mg/kg) and xylazine (4 mg/kg). Body temperature was
maintained with a heating pad at 37.5 6 1 8C throughout the
recording. The pupils were fully dilated with 0.5% tropicamide and
2.5% phenylephrine HCl, and both eyes were recorded simulta-
neously. Corneal gold-wire loops were used as the active electrodes
under 0.5% proparacaine hydrochloride topical anesthesia. Gold-
wire electrodes placed on the sclera near the limbus served as
reference electrodes. A ground wire was attached to the ear. Scotopic
responses were recorded from threshold to 9 log units of intensity
above threshold, ampliﬁed, and ﬁltered (5,000 gain, 0.1–1,000 Hz). For
photopic recordings background light at 34 cd/m
2 was used to
suppress rod function.
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Figure S1. Western Blot Analysis of the Association of LD of RanBP2
with HKI and Cox11 across Tissues
GST-JX2 (2.2 lM) was incubated with different tissue extracts (;2.0
mg) and the GST-JX2 coprecipitates from seven different tissues were
analyzed by Western blot with the antibodies against HKI and Cox11.
The LD of RanBP2 associated with the HKI and Cox11 in all seven
tissues tested.
Found at DOI: 10.1371/journal.pgen.0020177.sg001 (59 KB PDF).
Figure S2. Immunostaining of Radial Cryosections of Wild-Type (þ/þ)
and Heterozygote (þ/ ) RanBP2 Mice Retinas with Anti-HKI and
 Cox11 Antibodies
A1 and B1 represent magniﬁcations of just the distal section of the
retina (inner segment subcellular compartment of the photosensory
neuron layer). Note the partial delocalization of HKI to the myoid
subcompartment of the inner segment of photoreceptor neurons in
þ/  mice (B1) and decreased levels of HKI in the inner plexiform
(synaptic) layer of the retina (A and B). This is reﬂected by a
signiﬁcant increase and decrease of the mean ﬂuorescence intensity
(in arbitrary units) of HKI in the myoid and inner plexiform
(synaptic) layers, respectively (E). AU, arbitrary unit; ROS, rod outer
segment; RIS, rod inner segment; ONL, outer nuclear layer; OPL,
outer plexiform layer, INL, inner nuclear layer; IPL, inner plexiform
layer; GCL, ganglion cell layer; E and M are, respectively, the ellipsoid
(mitochondria-rich) and myoid compartments of photosensory
neurons.
Found at DOI: 10.1371/journal.pgen.0020177.sg002 (476 KB PDF).
Figure S3. Metabolic Phenotype of RanBP2
þ/  Mice in a Mixed
Background and High-Fat Diet
There was no difference in the glucose tolerance test between
RanBP2
þ/þ and RanBP2
þ/ mice on a mixed 129Ola/C57Bl6 genetic
background (C).
Found at DOI: 10.1371/journal.pgen.0020177.sg003 (38 KB PDF).
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